Literature DB >> 10389761

MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.

M Hartman1, A Baruch, I Ron, Y Aderet, M Yoeli, O Sagi-Assif, S Greenstein, Y Stadler, M Weiss, E Harness, M Yaakubovits, I Keydar, N I Smorodinsky, D H Wreschner.   

Abstract

The products of the MUC1 gene are known to be highly expressed in human breast cancer cells. The best characterized MUC1 protein is a polymorphic, type 1 transmembrane molecule containing a large extracellular domain composed primarily of a variable number of 20 amino acid tandem repeats. We have recently identified a novel protein product of the MUC1 gene, the MUC1/Y protein, that is also a transmembrane protein but is devoid of the tandem repeat array and its immediate flanking sequences. To analyze its expression in tumor cells we generated monoclonal antibodies directed against the MUC1/Y extracellular domain (anti-MUC1/Yex MAbs). Epitope mapping identified the MAb, 6E6, which recognized the MUC1/Y isoform with exquisite specificity- the repeat-array-containing MUC1 isoform could not compete out this immunoreactivity. A 30mer peptide which is unique for MUC1/Y and corresponds to the "join" region generated by the MUC1/Y specific splice, abrogated all 6E6 MAb immunoreactivity towards MUC1/Y. Immunoprecipitation of the MUC1/Y protein with 6E6 MAbs revealed that, in contrast with the proteolytic cleavage of the tandem-repeat-array-containing MUC1 isoform, MUC1/Y is not cleaved. Flow cytometry analyses using the 6E6 MAbs demonstrated that the MUC1/Y isoform is expressed on the cell surface of both MCF-7 breast cancer cells and malignant epithelial cells present in effusions obtained from breast and ovarian cancer patients. Our results unequivocally establish that the MUC1/Y protein is expressed on the surface of breast cancer cells and cells of other epithelial malignancies. The anti-MUC1/Y MAbs described here can target MUC1/Y expressing tumor cells in vivo and are likely to be important reagents both for epithelial tumor diagnosis and immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389761     DOI: 10.1002/(sici)1097-0215(19990719)82:2<256::aid-ijc17>3.0.co;2-c

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

Review 2.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

3.  C-terminal domain of rodent intestinal mucin Muc3 is proteolytically cleaved in the endoplasmic reticulum to generate extracellular and membrane components.

Authors:  Rongquan Wang; Ismat A Khatri; Janet F Forstner
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

4.  Human preocular mucins reflect changes in surface physiology.

Authors:  M Berry; R B Ellingham; A P Corfield
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

5.  Unfolding dynamics of the mucin SEA domain probed by force spectroscopy suggest that it acts as a cell-protective device.

Authors:  Thaher Pelaseyed; Michael Zäch; Asa C Petersson; Frida Svensson; Denny G A Johansson; Gunnar C Hansson
Journal:  FEBS J       Date:  2013-02-21       Impact factor: 5.542

Review 6.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

Review 7.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

8.  Genetic regulation of MUC1 alternative splicing in human tissues.

Authors:  W Ng; A X W Loh; A S Teixeira; S P Pereira; D M Swallow
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.